Ranbaxy Suspends API Shipments from Two Plants in India - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ranbaxy Suspends API Shipments from Two Plants in India

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 3

Ranbaxy Laboratories has announced that it has temporarily suspended shipments of active pharmaceutical ingredients (APIs) produced at its Toansa and Dewas plants in India.

On Jan. 24, the company announced that API shipments from the Toansa plant to the United States were suspended. The company says it has now voluntarily suspended all API shipments from both the Toansa and Dewas plants in order to allow for further evaluation and inspection of manufacturing processes and quality control systems. The temporarily suspended shipments will be resumed once the processes and controls at these facilities are reconfirmed based on internal evaluations and inspections.

Ranbaxy has also announced that a Quality and Integrity Committee, established as a sub-committee of the Ranbaxy Corporate Board of Directors in order to improve corporate governance, has been in operation from early February 2014. 

In a statement, parent company Daiichi Sankyo issued an apology to all its stakeholders “for the inconvenience caused by the further suspension of API shipments this time. As Ranbaxy is one of our most important affiliates in the Group, Daiichi Sankyo is committed to continuing to offer full support for Ranbaxy to improve quality standards,” the statement read.

Source: Daiichi Sankyo

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here